Recruiting NCT02039752
Asan Multivessel Registry
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Treatment.
- Who it may be relevant to
- Registry conditions: Coronary Artery Disease. Basic parameters: from 19 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- South Korea
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Asan Medical Center Registry for Multivessel
Overview
The purpose of this study is to evaluate long-term prognoses of patients with multivessel coronary disease treated medically or surgically or percutaneously in real world practice.
Interventions
- Other Treatment
Primary outcome measures
- composite event [Time frame: 1year]
Secondary outcome measures (8)
- Death [Time frame: 1year]
- Myocardial Infarction [Time frame: 1year]
- Stroke [Time frame: 1year]
- Revascularization [Time frame: 1year]
- Angina symptom [Time frame: 1year]
- Bleeding [Time frame: 1year]
- Re-hospitalization [Time frame: 1year]
- Stent thrombosis [Time frame: 1year]
Eligibility criteria
Inclusion criteria
- Patients with multivessel disease from 1995 in Asan Medical Center
- Age 19 and more
Exclusion criteria
- For prospective cohort, not agreeing to participate with written informed consent form
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
South Korea · 1 center
- Asan Medical Center — Seoul
Publications
- Park J, Kim SH, Kim M, Lee J, Choi Y, Kim H, Kim TO, Kang DY, Ahn JM, Yoo JS, Kim HJ, Kim JB, Choo SJ, Chung CH, Park SJ, Park DW; Asan-Multivessel Registry Investigators. Impact of Optimal Medical Therapy on Long-Term Outcomes After Myocardial Revascularization for Multivessel Coronary Disease. Am J Cardiol. 2023 Sep 15;203:81-91. doi: 10.1016/j.amjcard.2023.06.083. Epub 2023 Jul 21. PMID 37481816
- Kim TO, Kang DY, Ahn JM, Kim SO, Lee PH, Lee J, Kim JH, Kim HJ, Kim JB, Choo SJ, Chung CH, Lee JW, Park SJ, Park DW; Asan Medical Center-Multivessel Revascularization Registry Investigators. Prognostic Impact of Mildly Impaired Renal Function in Patients Undergoing Multivessel Coronary Revascularization. J Am Coll Cardiol. 2022 Apr 5;79(13):1270-1284. doi: 10.1016/j.jacc.2022.01.035. PMID 35361350
- Kim TO, Ahn JM, Kang DY, Park H, Kim SO, Lee PH, Lee J, Kim JH, Jeong YJ, Yang Y, Hyun J, Kim HJ, Kim JB, Choo SJ, Chung CH, Lee JW, Park SJ, Park DW; Asan-Multivessel Registry Investigators. Long-Term Outcomes After Percutaneous Coronary Intervention With Second-Generation Drug-Eluting Stents or Coronary Artery Bypass Grafting for Multivessel Coronary Disease. Am J Cardiol. 2021 Dec 1;160:21-30. PMID 34610874
Identifiers
NCT: NCT02039752 · AMCCV2013-15